Feb 24, 2022
RNS Number : 7185C MaxCyte, Inc. 24 February 2022   MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022   GAITHERSBURG, MD , February 24, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing
Feb 22, 2022
RNS Number : 4691C MaxCyte, Inc. 22 February 2022   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name   MAXCYTE, INC.   UK or Non- UK Issuer Non- UK   2. Reason for Notification An acquisition or disposal of voting rights 3.
Feb 21, 2022
RNS Number : 2025C MaxCyte, Inc. 21 February 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Consolidation of Trading Lines   Total voting rights       Gaithersburg, Maryland - 21 February 2022:      MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling   platform
Feb 14, 2022
GAITHERSBURG, Md., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
Feb 14, 2022
RNS Number : 5088B MaxCyte, Inc. 14 February 2022   MaxCyte to Participate in Upcoming Investor Conferences GAITHERSBURG, MD , February 14, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies
Feb 14, 2022
RNS Number : 5087B MaxCyte, Inc. 14 February 2022   MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , February 14, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform
Feb 01, 2022
RNS Number : 2329A MaxCyte, Inc. 01 February 2022                                                                                                         MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs   Intima Bioscience to use
Displaying 41 - 50 of 52